The webinar provides a detailed overview of the considerations and guidelines for conducting Fcγ receptor binding studies, particularly for IgG1, IgG2, and IgG4 monoclonal antibodies. These studies are critical for understanding the therapeutic efficacy and immune system engagement of these antibodies. The document emphasizes the importance of accurate assay design and development, highlighting the use of the Octet® BLI Platform for real-time, label-free analysis of biomolecular binding interactions.
Senior Scientist – Sartorius
Dr Stuart Knowling is a Senior Application Scientist and has over a decade of experience in biophysics and has headed up multiple projects for drug companies in preparation for submissions. Combined with almost twenty years’ worth of experience in biophysical protein and nucleic acid production and characterization. After research appointments at both University College San Diego and the Scripps Research Institute, La Jolla, Stuart adapted his knowledge of biophysical techniques to meet the growing demands of the biosimilars market. Stuart has initiated and developed multiple BLI and SPR assay formats to characterize biosimilar monoclonal antibody-based therapies as part of larger similarity studies. Stuart also has a strong focus on developing target binding assays across a range of protein and non-protein molecules to meet the needs of his clients at all stages of submission to regulatory bodies. He is highly active in presenting his work across the globe and is the lead author on multiple documents and continues to advance Octet® BLI and SPR so that users can generate high quality data in the simplest manner possible.